More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes
Gulsevin A, Papke RL, Stokes C, Garai S, Thakur GA, Quadri M, Horenstein NA (2019) Allosteric agonism of a7 nicotinic acetylcholine receptors: Receptor modulation outside the orthosteric site S
Clinical trial objectives The purpose of the clinical study in humans was to evaluate the efficacy of four weeks supplementation of a combination of vitamin B6, B9, B12, and taurine on motivated behavior, as a primary outcome, and on attentional performance, and self-reported mood (e.g., fatigue, vigor) as secondary outcomes
Glutathione is a bit more subtle as a reducing agent let me explain what I mean by that